Меню
Идёт набор NCT03408964

Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients

— Наблюдательное Prostate Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: biological samples collection and analysis.
Кому может быть актуально
Состояния в реестре: Prostate Cancer. Базовые параметры: от 18 лет · Мужчины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Швейцария
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

An Exploratory proof-of Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients, a Single Center Study

Обзор

Participants to the study will be assigned to 7 cohorts according to the stage of disease and planned antitumor treatment at time of study entry. In all patients, 12 ml of blood sample will be collected in EDTA tube for analysis of biological biomarkers in different time points.

Подробное описание

Participants to the study will be assigned to 5 cohorts according to the stage of disease and planned antitumor treatment at time of study entry.

Group 0 (set-up): blood sampling and rectal swab will be collected at a single time-point during the PC treatment. No follow-up is required.

Group 1a (control): the first blood sampling will be performed within 4 weeks since the negative biopsy; subsequent samplings will be done according to a schedule comparable to that of Group 1 up to 1 year or evidence of tumor, whichever occurs first.

Group 1, Group 2 and Group 3: the first blood sampling will be performed before radical treatment or HT start or CT start, on the basis of the planned antitumor therapy; subsequent sampling will be done after radical intervention at 4 weeks (only for Group 1) and then every 3 months (or more frequently if clinically indicated), up to 3 years or evidence of tumor recurrence/progression (radiological or biochemical), whichever occurs first.

At the time of recurrence/progression, patients of Group 1 could become part and could be followed as per Group 2, and patients of Group 2 could become part and could be followed as per Group 3.

Group Exo and Group Bio: blood sampling will be performed at a single time-point during the PC treatment. No follow-up is required.

Вмешательства

  • Другое biological samples collection and analysis
    Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule

Первичные конечные точки

  • Biomarkers value in the response to therapy [Срок оценки: 3 years]
Вторичные конечные точки (3)
  • Biomarkers inter and intra variability [Срок оценки: 3 years]
  • Metabolomic and metagenomic analysis [Срок оценки: 3 years]
  • Metabolomic and metagenomic analysis [Срок оценки: 3 years]

Критерии участия

Критерии включения

General inclusion criteria (for entering all groups)

  • Age ≥ 18 years
  • Histological diagnosis of prostate adenocarcinoma at different stages of disease (see Section 6.2) for which a treatment is indicated
  • Written Informed Consent

Inclusion criterion only for entering Group 0

  • Patients with a known diagnosis of CSPC or CRPC

Inclusion criterion only for entering Group 1a

  • Patients that underwent biopsies for a suspect of PC, but resulted negative for cancer

Критерии исключения

General exclusion criteria (for entering all groups)

  • Active infection requiring treatment
  • Decrease of general condition
  • Concomitant severe comorbities
  • Difficult socioeconomic conditions making regular follow up unfeasible.
  • Need of concomitant steroids at study entry and during the study
  • Diagnosis of second tumor in the previous 5 years

Exclusion criterion only for entering Group 0

  • No antibiotic treatments in the previous 2 months before enrollment

Exclusion criteria only for entering Group 1

  • Previous radical surgery and / or radical radiotherapy
  • Previous hormonal treatments

Exclusion criteria only for entering Group 2

  • No antibiotic treatments in the previous 2 months before enrollment (only in patients enrolling also for metagenomics and metabolomics)
  • Previous hormonal treatments for advanced disease

Exclusion criterion only for entering Group 3

  • No antibiotic treatments in the previous 2 months before enrollment (only in patients enrolling also for metagenomics and metabolomics analyses)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Швейцария · 1 центр
  • Oncology Institute of Southern Switzerland (IOSI) — Bellinzona

Идентификаторы

NCT: NCT03408964 · IOSI-IOR-002

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗